The development of a recombinant hepatitis E vaccine HEV 239
Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 y old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. Th...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2015-04, Vol.11 (4), p.908-914 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 914 |
|---|---|
| container_issue | 4 |
| container_start_page | 908 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 11 |
| creator | Li, Shao-Wei Zhao, Qinjian Wu, Ting Chen, Shu Zhang, Jun Xia, Ning-Shao |
| description | Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 y old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. The quality of the vaccine is controlled through a combination of biophysical, biochemical and immunochemical methods. The vaccine is well tolerated in adults. The efficacy of the HEV 239 vaccine against symptomatic and asymptomatic infection had been proven to be high during a Phase III clinical trial and long-term follow up. The safety and efficacy of HEV 239 vaccine in certain high-risk populations remains to be further investigated. |
| doi_str_mv | 10.1080/21645515.2015.1008870 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_25714510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1677887509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-a4ca2ff0184311fc715ba8eba3286b2d911b44abd196b56d436fae42b7c46a23</originalsourceid><addsrcrecordid>eNp9kE9LMzEQxoMoKupHUPbopZrJJtktyIsi9Q8IXop4C5NsYiO7m5psK357U1rL68UckjDzzDMzP0JOgV4AreklA8mFAHHBaL6A0rqu6A45XMVHQvDX3e0fxAE5Semd5lNRxqXcJwdMVMAF0ENyNZ3ZorFL24Z5Z_uhCK7AIloTOu17zIGZnePgB5-KSbFEY3xvi4fJS8HK8THZc9gme7J5j8j0bjK9fRg9Pd8_3t48jYwo-TBCbpA5R6HmJYAzFQiNtdVYslpq1owBNOeoGxhLLWTDS-nQcqYrwyWy8oj8W9vOF7qzjcljRmzVPPoO45cK6NXvTO9n6i0sVV6RA6-zwfnGIIaPhU2D6nwytm2xt2GRFMiqygQFHWepWEtNDClF67ZtgKoVe_XDXq3Yqw37XHf2_4zbqh_SWXC9FvjehdjhZ4htowb8akN0EXvjkyr_7vENMi6SVA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1677887509</pqid></control><display><type>article</type><title>The development of a recombinant hepatitis E vaccine HEV 239</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Li, Shao-Wei ; Zhao, Qinjian ; Wu, Ting ; Chen, Shu ; Zhang, Jun ; Xia, Ning-Shao</creator><creatorcontrib>Li, Shao-Wei ; Zhao, Qinjian ; Wu, Ting ; Chen, Shu ; Zhang, Jun ; Xia, Ning-Shao</creatorcontrib><description>Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 y old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. The quality of the vaccine is controlled through a combination of biophysical, biochemical and immunochemical methods. The vaccine is well tolerated in adults. The efficacy of the HEV 239 vaccine against symptomatic and asymptomatic infection had been proven to be high during a Phase III clinical trial and long-term follow up. The safety and efficacy of HEV 239 vaccine in certain high-risk populations remains to be further investigated.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2015.1008870</identifier><identifier>PMID: 25714510</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Clinical Trials as Topic ; efficacy ; Hecolin ; Hepatitis E - immunology ; Hepatitis E virus ; HEV 239 ; Humans ; Product Review ; vaccine ; Vaccines, Synthetic - adverse effects ; Vaccines, Synthetic - immunology ; Vaccines, Synthetic - therapeutic use ; Viral Vaccines - adverse effects ; Viral Vaccines - immunology ; Viral Vaccines - therapeutic use</subject><ispartof>Human vaccines & immunotherapeutics, 2015-04, Vol.11 (4), p.908-914</ispartof><rights>2015 Taylor & Francis Group, LLC 2015</rights><rights>2015 Taylor & Francis Group, LLC 2015 Taylor & Francis Group, LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-a4ca2ff0184311fc715ba8eba3286b2d911b44abd196b56d436fae42b7c46a23</citedby><cites>FETCH-LOGICAL-c534t-a4ca2ff0184311fc715ba8eba3286b2d911b44abd196b56d436fae42b7c46a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514148/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514148/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25714510$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Shao-Wei</creatorcontrib><creatorcontrib>Zhao, Qinjian</creatorcontrib><creatorcontrib>Wu, Ting</creatorcontrib><creatorcontrib>Chen, Shu</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><creatorcontrib>Xia, Ning-Shao</creatorcontrib><title>The development of a recombinant hepatitis E vaccine HEV 239</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 y old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. The quality of the vaccine is controlled through a combination of biophysical, biochemical and immunochemical methods. The vaccine is well tolerated in adults. The efficacy of the HEV 239 vaccine against symptomatic and asymptomatic infection had been proven to be high during a Phase III clinical trial and long-term follow up. The safety and efficacy of HEV 239 vaccine in certain high-risk populations remains to be further investigated.</description><subject>Clinical Trials as Topic</subject><subject>efficacy</subject><subject>Hecolin</subject><subject>Hepatitis E - immunology</subject><subject>Hepatitis E virus</subject><subject>HEV 239</subject><subject>Humans</subject><subject>Product Review</subject><subject>vaccine</subject><subject>Vaccines, Synthetic - adverse effects</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Vaccines, Synthetic - therapeutic use</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - immunology</subject><subject>Viral Vaccines - therapeutic use</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9LMzEQxoMoKupHUPbopZrJJtktyIsi9Q8IXop4C5NsYiO7m5psK357U1rL68UckjDzzDMzP0JOgV4AreklA8mFAHHBaL6A0rqu6A45XMVHQvDX3e0fxAE5Semd5lNRxqXcJwdMVMAF0ENyNZ3ZorFL24Z5Z_uhCK7AIloTOu17zIGZnePgB5-KSbFEY3xvi4fJS8HK8THZc9gme7J5j8j0bjK9fRg9Pd8_3t48jYwo-TBCbpA5R6HmJYAzFQiNtdVYslpq1owBNOeoGxhLLWTDS-nQcqYrwyWy8oj8W9vOF7qzjcljRmzVPPoO45cK6NXvTO9n6i0sVV6RA6-zwfnGIIaPhU2D6nwytm2xt2GRFMiqygQFHWepWEtNDClF67ZtgKoVe_XDXq3Yqw37XHf2_4zbqh_SWXC9FvjehdjhZ4htowb8akN0EXvjkyr_7vENMi6SVA</recordid><startdate>20150403</startdate><enddate>20150403</enddate><creator>Li, Shao-Wei</creator><creator>Zhao, Qinjian</creator><creator>Wu, Ting</creator><creator>Chen, Shu</creator><creator>Zhang, Jun</creator><creator>Xia, Ning-Shao</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150403</creationdate><title>The development of a recombinant hepatitis E vaccine HEV 239</title><author>Li, Shao-Wei ; Zhao, Qinjian ; Wu, Ting ; Chen, Shu ; Zhang, Jun ; Xia, Ning-Shao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-a4ca2ff0184311fc715ba8eba3286b2d911b44abd196b56d436fae42b7c46a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Clinical Trials as Topic</topic><topic>efficacy</topic><topic>Hecolin</topic><topic>Hepatitis E - immunology</topic><topic>Hepatitis E virus</topic><topic>HEV 239</topic><topic>Humans</topic><topic>Product Review</topic><topic>vaccine</topic><topic>Vaccines, Synthetic - adverse effects</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Vaccines, Synthetic - therapeutic use</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - immunology</topic><topic>Viral Vaccines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Shao-Wei</creatorcontrib><creatorcontrib>Zhao, Qinjian</creatorcontrib><creatorcontrib>Wu, Ting</creatorcontrib><creatorcontrib>Chen, Shu</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><creatorcontrib>Xia, Ning-Shao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Shao-Wei</au><au>Zhao, Qinjian</au><au>Wu, Ting</au><au>Chen, Shu</au><au>Zhang, Jun</au><au>Xia, Ning-Shao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The development of a recombinant hepatitis E vaccine HEV 239</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2015-04-03</date><risdate>2015</risdate><volume>11</volume><issue>4</issue><spage>908</spage><epage>914</epage><pages>908-914</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 y old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. The quality of the vaccine is controlled through a combination of biophysical, biochemical and immunochemical methods. The vaccine is well tolerated in adults. The efficacy of the HEV 239 vaccine against symptomatic and asymptomatic infection had been proven to be high during a Phase III clinical trial and long-term follow up. The safety and efficacy of HEV 239 vaccine in certain high-risk populations remains to be further investigated.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>25714510</pmid><doi>10.1080/21645515.2015.1008870</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2015-04, Vol.11 (4), p.908-914 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_pubmed_primary_25714510 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Clinical Trials as Topic efficacy Hecolin Hepatitis E - immunology Hepatitis E virus HEV 239 Humans Product Review vaccine Vaccines, Synthetic - adverse effects Vaccines, Synthetic - immunology Vaccines, Synthetic - therapeutic use Viral Vaccines - adverse effects Viral Vaccines - immunology Viral Vaccines - therapeutic use |
| title | The development of a recombinant hepatitis E vaccine HEV 239 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T18%3A33%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20development%20of%20a%20recombinant%20hepatitis%20E%20vaccine%20HEV%20239&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Li,%20Shao-Wei&rft.date=2015-04-03&rft.volume=11&rft.issue=4&rft.spage=908&rft.epage=914&rft.pages=908-914&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2015.1008870&rft_dat=%3Cproquest_pubme%3E1677887509%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1677887509&rft_id=info:pmid/25714510&rfr_iscdi=true |